Webcast ImageWebcast
Q3 2018 Laboratory Corporation of America Holdings Earnings Conference Call (Live)
10/24/18 at 9:00 a.m. ET
Download DocumentationLabCorp Investor & Analyst Day Presentation
E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
10/10/18Walgreens and LabCorp to Open at Least 600 LabCorp at Walgreens Patient Service Centers
Strategic collaboration reflects both companies’ focus on providing customers access to affordable in-store health care services DEERFIELD, Ill. & BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 10, 2018-- Walgreens and LabCorp® (NYSE: LH) today announced their mutual commitment to a significant expansion of their LabCorp at Walgreens collaboration. The two companies have agreed to open at least 600 LabCorp patient service centers at Walgreens stores acr... 
Printer Friendly Version
10/01/18Conversion Right Triggered For LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 1, 2018-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006, between LabCorp and The Bank of New York Mellon, as trustee... 
Printer Friendly Version
09/25/18LabCorp to Announce Third Quarter Financial Results on October 24, 2018
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 25, 2018-- LabCorp® (NYSE: LH) will release its third quarter 2018 financial results before the market opens on Wednesday, October 24, 2018, and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results. The earnings release and accompanying financial information will be posted on the LabCorp Investor Relations website. Interested parties can access the conference... 
Printer Friendly Version
09/24/18LabCorp Teams up with Operation Airdrop to Deliver Much-Needed Supplies to North Carolina Communities Devastated by Hurricane Florence
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 24, 2018-- Over the weekend, LabCorp® (NYSE: LH) in coordination with Operation Airdrop delivered approximately 25,000 pounds of water, food, dog food, diapers, and other relief supplies as well as 1,000 hot meals aboard three of LabCorp’s Pilatus PC-12 cargo aircraft to aid in recovery efforts following Hurricane Florence. This press release features multimedia. View the full release here: https://www.businessw... 
Printer Friendly Version
09/24/18LabCorp Statement on District Court Opinion in ACLA Lawsuit against HHS
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 24, 2018-- LabCorp® (NYSE: LH) today issued the following statement regarding the decision from the U.S. District Court for the District of Columbia in ACLA v. Azar on Friday, Sept. 21, to dismiss the laboratory industry’s lawsuit to halt implementation of damaging cuts to Medicare reimbursement for lab testing: “We are deeply disappointed in the district court’s decision and believe that its conclus... 
Printer Friendly Version
09/11/18LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 11, 2018-- LabCorp® (NYSE: LH) announced today that for the period of September 11, 2018 to March 8, 2019, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended September 6, 2018, in addition to t... 
Printer Friendly Version
09/06/18LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 6, 2018-- LabCorp® (NYSE: LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference. LabCorp’s presentation is planned for Thursday, September 13, 2018 at 2:05 pm (ET). A live audio webcast will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an S&P 500 company, is a leading global ... 
Printer Friendly Version
08/16/18The National Football League Alumni, Cancer Treatment Centers of America®, LabCorp® and Health Testing Centers Team Up to Offer Prostate Cancer Screenings in September
Nearly one in nine men, one in six African-American men, will be diagnosed with prostate cancer BOCA RATON, Fla., Aug. 16, 2018 /PRNewswire/ -- Prostate cancer is the second most common cancer among men. To raise awareness of the disease and the benefits of early screening, the NFL Alumni (NFLA), Cancer Treatment Centers of America® (CTCA), LabCorp® (NYSE: LH ) and Health Testing Centers are collaborating for the second year as part of the Prostate Pep... 
Printer Friendly Version
07/25/18LabCorp Announces 2018 Second Quarter Results and Updates 2018 Guidance
Q2 revenue of $2.9 billion, up 13% over $2.5 billion last year Q2 diluted EPS of $2.27, up 28% from $1.78 last year; Q2 adjusted EPS of $2.98, up 23% over $2.43 last year Q2 free cash flow of $280 million, up 16% over $241 million last year 2018 adjusted EPS guidance of $11.35 to $11.65, up 23% to 26% over 2017 2018 free cash flow guidance of $1.1 billion to $1.2 billion ... 
Printer Friendly Version
07/12/18Robert E. Mittelstaedt, Jr. to Retire from LabCorp Board of Directors and Current Board Member Adam H. Schechter to Assume Role of Lead Independent Director in 2019
BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 12, 2018-- LabCorp® (NYSE: LH) today announced that Robert E. Mittelstaedt, Jr., lead independent director, will retire from the LabCorp board of directors at the conclusion of his current term on May 9, 2019, and that director Adam H. Schechter has been elected to serve as lead independent director effective January 2, 2019, so that he and Mittelstaedt may work together on a smooth transition. Mitte... 
Printer Friendly Version
07/02/18Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 2, 2018-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006, between LabCorp and The Bank of New York Mellon, as trustee... 
Printer Friendly Version
06/28/18LabCorp and Philips collaborate on digital pathology to enhance the efficiency of pathology diagnostics
BURLINGTON, N.C. and AMSTERDAM, June 28, 2018 /PRNewswire/ -- LabCorp® (NYSE: LH ), a leading global life sciences company that is deeply integrated in guiding patient care, and Royal Philips (NYSE: PHG , AEX: PHIA), a global leader in health technology, today announced a collaboration to further advance digital pathology. Through the implementation of the Philips IntelliSite Pathology Solution , LabCorp will in... 
Printer Friendly Version
06/27/18LabCorp Launches Proprietary UltraQual® Multiplex PCR Assay for HCV, HIV-1, HIV-2 and HBV
FDA-approved test offered exclusively from LabCorp’s National Genetics Institute supports faster, more precise identification of viral agents in blood plasma used to manufacture cutting-edge biologic treatments BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 27, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the UltraQual® Multiplex ... 
Printer Friendly Version
06/11/18LabCorp Expands Drug Development Solutions with Acquisition of Sciformix
Sciformix extends Covance’s pharmacovigilance capabilities for post-approval safety solutions BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 11, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that it has acquired Sciformix Corporation, a scientific process outsourcing company focused on pharmacovigilance and regulatory solutions for biopharmaceutical and medical devices clients. Sciformix will become part of Covan... 
Printer Friendly Version
06/05/18LabCorp is Scheduled to Present at the 38th Annual William Blair Growth Stock Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 5, 2018-- LabCorp® (NYSE: LH) today announced it will participate at the 38th Annual William Blair Growth Stock Conference. LabCorp’s presentation is planned for Tuesday, June 12, 2018 at 12:10 PM (CT). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an S&P 500 c... 
Printer Friendly Version
06/01/18LabCorp and Unilabs Collaborate to Expand Global Reach of Precision Medicine Capabilities to Serve Patients, Physicians and Pharma
Collaboration creates global laboratory network for the development and commercialization of companion diagnostics BURLINGTON, N.C. & GENEVA--(BUSINESS WIRE)--Jun. 1, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, and Unilabs, a leading European provider of clinical laboratory testing and medical diagnostic imaging services, announced a strategic collaboration to provide expanded global development and delivery of companion ... 
Printer Friendly Version
05/25/18LabCorp to Become a Preferred National Laboratory for Aetna
Agreement Expands Access to High-Quality, High-Value Laboratory Services for All Aetna Members HARTFORD, Conn. & BURLINGTON, N.C.--(BUSINESS WIRE)--May 25, 2018-- Aetna (NYSE: AET) and LabCorp® (NYSE: LH) today extended and expanded their existing agreement, making LabCorp a preferred national laboratory for substantially all of Aetna’s members beginning January 1, 2019. The expanded agreement will provide more than 20 million eligible mem... 
Printer Friendly Version
05/24/18UnitedHealthcare Establishes Long-term Strategic Partnership with LabCorp
  LabCorp will continue participating as a national provider of laboratory services to all UnitedHealthcare plan participants  Partnership will include broad range of value-based programs, rewarding high-quality, easily accessible laboratory services at the best value and real-time data sharing to drive more personalized care support  MINNEAPOLIS & BURLINGTON, N.C.--(BUSINESS WIRE)--UnitedHealthcare and LabCorp (NYSE: LH) have renewed their long-term strategic partnership as t... 
Printer Friendly Version
05/03/18LabCorp to Webcast Its Annual Meeting of Shareholders
BURLINGTON, N.C.--(BUSINESS WIRE)--May 3, 2018-- LabCorp® (NYSE: LH) today announced that its Annual Meeting of Shareholders will be webcast live beginning May 10, 2018 at 9:00 a.m. Eastern Daylight Time via the Company website at www.labcorp.com. An archived replay of the audio webcast will be available for one year. About LabCorp LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply ... 
Printer Friendly Version
05/01/18LabCorp Announces Collaboration with The Recovery Platform to Assist Physicians Treating Patients with Opioid Dependency
Combination of LabCorp’s testing and The Recovery Platform’s software supports compliance with medication-assisted treatment BURLINGTON, N.C.--(BUSINESS WIRE)--May 1, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, and The Recovery Platform are announcing a new collaboration to expand access to medication-assisted opioid treatment on a national basis. The Recovery Platform is a unique monitoring tool designed to help primary care ... 
Printer Friendly Version
04/30/18LabCorp Enters into Definitive Agreement to Sell Covance Food Solutions to Eurofins for $670 Million
Transaction reflects LabCorp’s mission to improve health and improve lives, and Eurofins’ commitment to be a scientific leader in laboratory services for the food supply industry BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 30, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that it has entered into a definitive agreement under which Eurofins Scientific (EUFI.PA), a global group of laboratories active in food, en... 
Printer Friendly Version
04/25/18LabCorp Announces Strong 2018 First Quarter Results and Updates 2018 Guidance
Effective January 1, 2018, the Company adopted the new revenue recognition accounting standard (ASC 606) and restated financial results for 2016 and 2017. Unless otherwise indicated, all financial results in 2017 and comparisons to financial results in 2017 have been restated in these bullets and this press release as if the Company had adopted ASC 606 on January 1, 2017. See “Adoption of ASC 606” below for additional details ... 
Printer Friendly Version
04/24/18LabCorp and Mount Sinai Health System Enhance Laboratory Operations to Improve Patient Care
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 24, 2018-- LabCorp® (NYSE: LH) and the Mount Sinai Health System today announced a significant milestone in achieving their common goal of improving laboratory services and patient care. LabCorp, a leading global life sciences company, and Mount Sinai, one of the largest health systems in metropolitan New York City, have begun to implement a program to standardize and optimize inpatient laboratory services across t... 
Printer Friendly Version
04/23/18LabCorp at Walgreens Expands into Florida
Ten new patient service centers to open at Walgreens stores in April and May DEERFIELD, Ill. & BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 23, 2018-- Walgreens and LabCorp® (NYSE: LH) today announced the expansion of their LabCorp at Walgreens collaboration into Florida. Ten new LabCorp patient service centers will open within Walgreens stores in April and May, with four serving the Gainesville market and two each serving the Palm Beach County... 
Printer Friendly Version
04/02/18Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 2, 2018-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006, between LabCorp and The Bank of New York Mellon, as trustee... 
Printer Friendly Version
03/22/18LabCorp and Appalachian Regional Healthcare Create Comprehensive Laboratory Collaboration
LabCorp’s Expertise in Health System Collaborations will Benefit Patients across Eastern Kentucky and Southern West Virginia BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 22, 2018-- LabCorp® (NYSE: LH) and Appalachian Regional Healthcare have entered into a multi-year, comprehensive laboratory partnership. Through the collaboration, LabCorp Diagnostics will provide technical services for Appalachian Regional Healthcare’s hospital-based labs, reference test... 
Printer Friendly Version
03/12/18LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 12, 2018-- LabCorp® (NYSE: LH) announced today that for the period of March 12, 2018 to September 11, 2018, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to the terms of the Zero Coupon Notes) contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 9, 2018, in addition to the ... 
Printer Friendly Version
03/09/18Covance Forms Immunology & Immunotoxicology Unit Focused on Biologic Drug Development
Global Team Addresses the Unique Scientific Needs of Safety Assessment for Biologics BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 9, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business has formed a global immunology and immunotoxicology (I&I) unit dedicated to the specific needs of biologic drug development. This team brings together Covance’s operational exper... 
Printer Friendly Version
03/07/18LabCorp is Scheduled to Present at the 2018 Barclays Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 7, 2018-- LabCorp® (NYSE: LH) today announced it will participate at the 2018 Barclays Global Healthcare Conference. LabCorp’s presentation is planned for Wednesday, March 14, 2018 at 9:30 am (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an S&P 500 company, is a ... 
Printer Friendly Version
03/05/18LabCorp Partners with Cheeriodicals through Community Service Campaign to Florida Hospital Memorial Medical Center and Halifax Health Medical Center
DAYTONA, Fla.--(BUSINESS WIRE)--Mar. 5, 2018-- As part of a community service campaign, an enthusiastic group of LabCorp employees teamed up with Cheeriodicals to assemble and deliver 128 big green boxes to children patients at Florida Hospital Memorial Medical Center and Halifax Health Medical Center during a “Cheeriodicals Day” event held last week. Cheeriodicals are “big green boxes of cheer” made up of age-appropriate magazines and activity bo... 
Printer Friendly Version
02/28/18Covance Enters into Strategic Technology Agreement with GSK
Leverages Covance’s Xcellerate® Informatics Technology Across GSK’s Global Clinical Trials Portfolio BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 28, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business has entered into a strategic technology agreement with GlaxoSmithKline plc (GSK). Under the terms of the agreement, GSK will use Covance’s Xcellerate® Monitoring, Xc... 
Printer Friendly Version
02/23/18LabCorp is Scheduled to Present at the 39th Annual Raymond James Institutional Investors Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 23, 2018-- LabCorp® (NYSE: LH) today announced it will participate at the 39th Annual Raymond James Institutional Investors Conference. LabCorp’s presentation is scheduled for Tuesday, March 6, 2018 at 8:40 AM (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an ... 
Printer Friendly Version
02/20/18LabCorp to Host Investor and Analyst Day on February 27, 2018
BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 20, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, will host an Investor and Analyst Day for institutional investors and financial analysts in New York City on Tuesday, February 27, 2018. The event, which will feature presentations by members of the management team, begins at 8:30 a.m. ET and will conclude by approximately 1:30 p.m. Prior registration is required to attend the event. ... 
Printer Friendly Version
02/06/18LabCorp Announces Record 2017 Fourth Quarter and Full Year Results and Provides 2018 Guidance
Net Revenue: Q4 of $2.7 billion, up 13% over 2016; Full year of $10.2 billion, up 8% over 2016 Diluted EPS: Q4 of $6.81, up 289% over 2016; Full year of $12.21, up 74% over 2016 Adjusted EPS: Q4 of $2.45, up 14% over 2016; Full year of $9.60, up 9% over 2016 Free Cash Flow: Q4 of $468 million, up 25% from 2016; Full year of $1.1 billion, up 28% over 2016 2018 Ad... 
Printer Friendly Version
01/19/18LabCorp Named to FORTUNE Magazine's 2018 List of ‘World’s Most Admired Companies’
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 19, 2018-- Laboratory Corporation of America® Holdings (LabCorp) (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE magazine's 2018 List of World’s Most Admired Companies. The annual survey, conducted by FORTUNE and the Hay Group division of Korn Ferry, a global people and organizational advisory firm, is given to top executives, directors and financial anal... 
Printer Friendly Version
01/08/18Covance Introduces Dedicated Offering Designed for Biotech, Medical Device and Diagnostics Companies
Distinctive development solutions provided by Chiltern®, a Covance® company BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 8, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business has introduced a dedicated offering for biotech, medical device and diagnostics companies from Chiltern®, a Covance® company. This unique offering follows the acquisition of Chiltern, a leadi... 
Printer Friendly Version
01/03/18LabCorp is Scheduled to Present at the 36th Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 3, 2018-- LabCorp® (NYSE: LH) today announced it will participate at the 36th Annual J.P. Morgan Healthcare Conference. LabCorp’s presentation is scheduled for Tuesday, January 9, 2018 at 9:30 am (PT). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an S&P 500 co... 
Printer Friendly Version
01/02/18Conversion Right Triggered For LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 2, 2018-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee ... 
Printer Friendly Version
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet